falsefalse

Evolving Treatment Landscape in Myelodysplastic Syndromes - Episode 16

Takeaways from ASH 2023 in Higher-Risk MDS

, , ,

Experts on myelodysplastic syndromes offer their key takeaways from the 2023 ASH Annual Meeting in the higher-risk disease space.

Current Time 0:00
Duration 5:40
Loaded: 0%
Stream Type LIVE
Remaining Time 5:40
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
EP. 1: Diagnosis of Myelodysplastic Syndromes (MDS)
EP. 2: Risk Stratification of Myelodysplastic Syndromes
EP. 3: First-Line Treatment of Lower-Risk MDS with Symptomatic Anemia
EP. 4: Patient Profile 1: A 72-Year-Old Man With MDS
EP. 5: Second-Line Treatment of Lower-Risk MDS With Symptomatic Anemia
EP. 6: Patient Profile 2: A 77-Year-Old Man With MDS
EP. 7: Unmet Needs and Adverse Event Management for Patients With Lower-Risk MDS and Symptomatic Anemia
EP. 8: ESA Treatment Selection in MDS
EP. 9: Updates from COMMANDS Trial: Luspatercept in Lower-Risk MDS
EP. 10: Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS
EP. 11: IMerge: Imetelstat in Patients With Lower-Risk MDS
EP. 12: Cytopenias Following Imetelstat Treatment in Lower-Risk MDS
EP. 13: Emerging Clinical Trials in MDS and Key Takeaways from ASH 2023
EP. 14: Treatment Options and Unmet Needs in Higher-Risk MDS
EP. 15: Updates from ASH 2023 in Higher-Risk MDS
Now Viewing
EP. 16: Takeaways from ASH 2023 in Higher-Risk MDS
EP. 17: Closing Thoughts on the MDS Treatment Landscape

Related Content:

Evolving Treatment Landscape in Myelodysplastic SyndromesSidney Kimmel Comprehensive Cancer Center at Johns HopkinsRobert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern MedicineHematologic OncologyOncLive Peer Exchange®
The OncFive: Top Oncology Articles for the Week of 7/6
Dr Danilov on Sequencing CAR T-Cell Therapy and Bispecific Antibodies in DLBCL
Dr Baggio on Prognostic Patterns of CNS Relapse in LBCL
x